Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD | Market Cap | 2.73B +23.4% |
| Revenue (ttm) | 98.02M +1,053.2% |
| Net Income | -141.48M |
| EPS | -0.11 |
| Shares Out | 1.30B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,225,184 |
| Average Volume | 2,332,132 |
| Open | 2.110 |
| Previous Close | 2.110 |
| Day's Range | 2.020 - 2.110 |
| 52-Week Range | 1.527 - 3.310 |
| Beta | 0.79 |
| RSI | 44.16 |
| Earnings Date | May 25, 2026 |
About Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammato... [Read more]
Financial Performance
In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.
Financial numbers in USD Financial StatementsNews
Mesoblast (MESO) Reports Strong Q1 Sales for Ryoncil®
Mesoblast (MESO) Reports Strong Q1 Sales for Ryoncil®
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob...
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase ...
Mesoblast Acquires CAR Technology From Mayo Clinic To Enhance MSC Therapies
(RTTNews) - Mesoblast Limited (MESO), a company specializing in allogenic cellular medicines, on Tuesday announced the acquisition of worldwide licensing rights to a patented chimeric antigen receptor...
Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up
(RTTNews) - Mesoblast Limited (MESO, MSB.AX) announced the acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform. This innovation is designed ...
Mesoblast (MESO) Secures Global License for Advanced CAR Technology
Mesoblast (MESO) Secures Global License for Advanced CAR Technology
Mesoblast acquires chimeric antigen receptor platform technology
Mesoblast (MESO) “announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor – CAR – technology platform for precision-enhanced augmentation of therapeutic m...
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an...
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts
Mesoblast (MESO) Gains on FDA Clearance for Duchenne Therapy Study
Mesoblast (MESO) Gains on FDA Clearance for Duchenne Therapy Study
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Mesoblast outlines commercial strategy to double net revenues as Ryoncil ® approaches US$100M net revenue milestone since launch last year
Mesoblast Transcript: R&D Day 2026
RYONCIL is driving strong revenue growth and label expansion, while late-stage programs in back pain and heart failure target multi-billion dollar markets. Next-generation MSC innovations and strategic partnerships support a robust pipeline, with financial discipline and manufacturing advances enabling sustainable growth.
Mesoblast receives IND clearance from FDA for Ryoncil trial
Mesoblast (MESO) announced that the FDA has granted investigational new drug clearance to directly proceed for a registrational clinical trial evaluating Ryoncil in Duchenne muscular dystrophy, which ...
Mesoblast Wins FDA IND Clearance To Fast-Track Ryoncil Trial In Duchenne Muscular Dystrophy
(RTTNews) - Mesoblast Limited (MESO), a commercial-stage biotechnology firm, announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to...
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) ...
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling over 100 points on Tuesday. Shares of Mach Natural Resources LP (NYSE: MNR) fell sharply in pre-market trading . Mach N...
Mesoblast (MESO) Reports Strong Ryoncil Sales in Latest Quarter
Mesoblast (MESO) Reports Strong Ryoncil Sales in Latest Quarter
Mesoblast reports $30.3M in Ryoncil sales in March quarter
Mesoblast (MESO) announced Ryoncil net sales were $30.3M for the quarter ended March 31. Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first
Mesoblast Reports $30.3 Mln Ryoncil Net Sales In Q3; Nearing $100 Mln Revenue Since Launch
(RTTNews) - Mesoblast Limited (MESO) has completed its first year since launching its lead product, Ryoncil, and has reached nearly $100 million in revenue.
Mesoblast (MESO) Reports Strong Ryoncil Sales Performance
Mesoblast (MESO) Reports Strong Ryoncil Sales Performance
Mesoblast reports March quarter Ryoncil sales of $30.3M
Mesoblast (MESO) “announced Ryoncil net sales were $30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated duri...
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global ...
Mesoblast to Host R&D Day on April 8, 2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wedn...
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Tere...